ONCOTHYREON INC. Patent applications |
Patent application number | Title | Published |
20140275234 | COMPOSITIONS AND METHODS OF USING CRYSTALLINE FORMS OF WORTMANNIN ANALOGS - Provided herein are novel crystalline forms of Compound 1. Also provided herein are compositions and methods of uses for the crystalline forms of Compound 1. | 09-18-2014 |
20130131156 | Cancer Treatment with Wortmannin Analogs - Provided herein are certain therapeutically effective dosing regimens for treatment of cancers with wortmannin analogs. | 05-23-2013 |
20130129720 | Combination Cancer Therapies with Wortmannin Analogs - Provided herein are combination therapies for the treatment of certain cancers in a subject by administering a combination of a therapeutic and a wortmannin analog to that subject. | 05-23-2013 |
20120282329 | MUC1 Based Glycolipopeptide Vaccine with Adjuvant - Provided herein are liposomal glycolipopeptidic vaccine formulations comprising an adjuvant and an immunogen for immunotherapy and/or treatment of cancer. | 11-08-2012 |
20120219617 | MUC1 Based Glycolipopeptide Vaccine with Adjuvant - Provided herein are liposomal glycolipopeptidic vaccine formulations comprising an adjuvant and an immunogen for immunotherapy and/or treatment of cancer. | 08-30-2012 |
20120034294 | METHOD OF MAKING SMALL LIPOSOMES - Liposomes of constrained particle size are prepared by substantially continuously mixing substantially continuously flowing streams of water, and of an organic solvent contain lipid(s) capable of forming liposomes, and cooling the mixture so liposomes form, the ratio of the flow rate of the stream of water to the flow rate of the stream of organic solvent, and the rate of cooling of said mixture, being controlled so as to obtain a preparation of liposomes such that at least about 90% of the liposomes are of a particle size less than about 200 nm. | 02-09-2012 |
20120003295 | LIPID A AND OTHER CARBOHYDRATE LIGAND ANALOGS - The core structure of pentaerythritol has been used as a replacement for one or both sugars in lipid A, leading to the generation of a series of lipid A analogs. These lipid A analogs may further differ from lipid A with respect to, e.g., the number, nature and location of negatively charged groups, and the number, nature and location of the lipid chains. The lipid A analogs may be lipid A agonists useful as immunostimulatory agents, or lipid A antagonists useful in the treatment of septic shock. In a like manner, a residue of pentaerythritylamine may be used as a replacement for an amino sugar residue in a carbohydrate ligand having a biological activity of interest, generating a series of ligand analogs. These are useful, e.g., as haptens, inhibitors of bacterial-host cell adhesion, etc. | 01-05-2012 |